These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11484952)

  • 1. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
    Backus HH; van Riel JM; van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
    Ann Oncol; 2001 Jun; 12(6):779-85. PubMed ID: 11484952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
    Backus HH; Dukers DF; van Groeningen CJ; Vos W; Bloemena E; Wouters D; van Riel JM; Smid K; Giaccone G; Pinedo HM; Peters GJ
    Ann Oncol; 2001 Feb; 12(2):209-16. PubMed ID: 11300326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.
    Backus HH; Van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
    J Clin Pathol; 2002 Mar; 55(3):206-11. PubMed ID: 11896073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
    Yamagishi S; Shimada H; Ishikawa T; Fujii S; Tanaka K; Masui H; Yamaguchi S; Ichikawa Y; Togo S; Ike H
    Anticancer Res; 2005; 25(2B):1237-42. PubMed ID: 15865071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.
    Kanavaros P; Stefanaki K; Valassiadou K; Vlachonikolis J; Mavromanolakis M; Vlychou M; Kakolyris S; Gorgoulis V; Tzardi M; Georgoulias V
    Med Oncol; 1999 Apr; 16(1):23-30. PubMed ID: 10382939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
    Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
    Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Casazza S; Antonelli G; Tunesi G; Baldo C; Lionetto R; Maley F; Sobrero A
    J Clin Oncol; 1999 Jun; 17(6):1760-70. PubMed ID: 10561213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
    Matsuyama R; Togo S; Shimizu D; Momiyama N; Ishikawa T; Ichikawa Y; Endo I; Kunisaki C; Suzuki H; Hayasizaki Y; Shimada H
    Int J Cancer; 2006 Jul; 119(2):406-13. PubMed ID: 16477629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
    Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
    J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
    Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
    Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
    Hillenbrand A; Formentini A; Staib L; Sander S; Salonga D; Danenberg K; Danenberg P; Kornmann M
    Eur J Surg Oncol; 2004 May; 30(4):407-13. PubMed ID: 15063894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
    Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.
    Gonen M; Hummer A; Zervoudakis A; Sullivan D; Fong Y; Banerjee D; Klimstra D; Cordon-Cardo C; Bertino J; Kemeny N
    J Clin Oncol; 2003 Feb; 21(3):406-12. PubMed ID: 12560427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
    Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
    Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
    Ishida H; Sadahiro S; Tajima T; Makuuchi H
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():233-6. PubMed ID: 14574888
    [No Abstract]   [Full Text] [Related]  

  • 18. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
    Chazal M; Cheradame S; Formento JL; Francoual M; Formento P; Etienne MC; François E; Richelme H; Mousseau M; Letoublon C; Pezet D; Cure H; Seitz JF; Milano G
    Clin Cancer Res; 1997 Apr; 3(4):553-7. PubMed ID: 9815719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
    Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
    Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.